Spravato treatment for Highland Beach — REMS-certified, insurance-covered TRD care.

RECO Integrated Psychiatry is a REMS-certified Spravato treatment site twelve minutes up A1A from Highland Beach. Sessions are administered by nurses trained in the esketamine protocol and overseen by a board-certified psychiatrist who also manages the concurrent oral antidepressant regimen — not an outside prescriber. For Bel Lido Isle and Toscana residents on a twice-weekly induction schedule, a short drive is the practical difference between an adherent eight-week induction and a missed one.

Highland Beach is the narrow oceanfront corridor between Delray and Boca Raton, and A1A puts RECO Integrated Psychiatry’s Delray campus about twelve minutes north. Residents of Bel Lido Isle, Toscana, and Boca Cove often bypass general behavioral-health offices in Boca in favor of a psychiatry practice equipped for treatment-resistant depression — including in-office Spravato administration under the FDA-mandated REMS protocol and integrated management of the concurrent oral antidepressant.

Spravato and the REMS protocol — what treatment actually looks like

Esketamine is delivered as a nasal spray, self-administered under nursing supervision at RECO’s certified Spravato treatment site. Standard induction dosing for treatment-resistant major depressive disorder is 56 mg at the first session, escalating to 84 mg at session two and beyond, with adjustments made for tolerability and hemodynamic response. Every session requires two hours of post-dose monitoring: blood pressure measurement at approximately 40 minutes (a transient elevation is expected and clinically anticipated), dissociative symptom assessment via the Clinician-Administered Dissociative States Scale (CADSS), and sedation monitoring until the patient meets discharge criteria.

Patients cannot drive after a Spravato session. Highland Beach patients typically arrange a ride home with a family member or a rideshare, and the office coordinates discharge timing so that clearance from the monitoring nurse aligns with pickup. REMS registration, dose logs, and adverse-event documentation are handled by the clinical team — that paperwork is a common source of billing denials at practices that treat Spravato as a side offering, and at a certified site it is routine.

Symptom tracking uses the PHQ-9 at baseline and at defined intervals through induction and maintenance, along with the C-SSRS where suicidality is a target of treatment. Progress notes reference specific PHQ-9 movement rather than global impression, which is what commercial payers require for continued authorization.

The induction and maintenance schedule

The FDA-approved schedule for treatment-resistant depression is twice-weekly sessions for the first four weeks — eight induction sessions total — followed by weekly sessions for weeks five through eight, then a taper to every one to two weeks based on symptom trajectory and functional recovery. Patients pursuing the acute suicidal ideation indication follow twice-weekly dosing for four weeks, with a separate maintenance decision made in consultation with the treating psychiatrist and any collaborating outpatient providers.

Clinical response is not immediate but is typically faster than with a newly initiated oral antidepressant. Many patients notice initial mood improvement within the first week; sustained response consolidates across the eight-session induction. Formal reassessment uses the PHQ-9 and GAD-7 alongside functional markers — sleep, appetite, occupational capacity, suicidal ideation. Non-response at the end of induction is a defined clinical decision point, not a reason to continue indefinitely.

Discontinuation from Spravato happens on a structured taper aligned with maintenance intervals, not abruptly. Esketamine cessation is not a physiological withdrawal event, but abrupt discontinuation carries a documented relapse risk in a population defined by prior treatment resistance.

Spravato works with an oral antidepressant, not instead of one

The FDA approval for esketamine is specifically as an adjunct to an oral antidepressant, not as monotherapy. Patients arriving on a partial-response SSRI or SNRI — sertraline, escitalopram, venlafaxine, duloxetine — typically continue that agent through induction, because the pivotal trials tested esketamine against ongoing antidepressant use, and commercial coverage is contingent on documented concurrent therapy.

Patients who have failed multiple prior trials sometimes begin or switch an oral agent at the same time as starting Spravato. A common scenario is transitioning off an SSRI that produced only partial response onto an SNRI, or adding an augmenting agent — aripiprazole, lithium, or quetiapine — based on symptom profile, prior tolerability, and metabolic risk. RECO’s psychiatry team manages this concurrent regimen directly rather than deferring it to an outside prescriber, so dose changes and side-effect adjustments happen in the same clinical loop as the Spravato sessions themselves.

Spravato versus IV ketamine — how the choice is made

Spravato and IV ketamine are related but clinically distinct. Spravato (esketamine) is FDA-approved for treatment-resistant depression and for major depressive disorder with acute suicidal ideation; IV ketamine uses the racemic molecule off-label and is not typically covered by commercial insurance. Spravato is nasal, self-administered, and fixed-dose at 56 mg or 84 mg; IV ketamine allows weight-based titration (commonly 0.5 mg/kg over 40 minutes) with response-based adjustment across a treatment series.

Time in office is broadly comparable. Spravato requires the full two hours of REMS-mandated post-dose monitoring per session; IV ketamine involves a 40-minute infusion with a shorter monitoring tail. Dissociation, transient blood-pressure elevation, and sedation are expected in both.

The practical determinants at consult are usually insurance coverage, prior treatment response, and dosing flexibility. RECO’s psychiatrists walk through both routes candidly, including what fixed-dose esketamine can and cannot accomplish for a patient who did not respond to prior racemic ketamine, and vice versa. There is no universal preference — the decision is made on intake against a documented history.

What to expect on your first visit

The first visit is a diagnostic psychiatric consultation, not a Spravato administration. Highland Beach patients are asked to bring a current medication list, prior prescriber notes when available, and any records of past antidepressant trials — agent, dose, duration, and outcome. The psychiatrist confirms the TRD diagnosis (documented failure of at least two adequate antidepressant trials in the current episode) or the acute suicidality indication, reviews cardiovascular history and baseline blood pressure, and screens for contraindications including uncontrolled hypertension, aneurysmal vascular disease, and recent hemorrhagic stroke.

A treatment plan is drafted at that visit and covers the oral antidepressant regimen, the induction schedule, and the transportation arrangement. REMS enrollment paperwork is completed at intake, and the first Spravato administration is typically scheduled within one to two weeks, after prior authorization is confirmed.

Insurance and admissions from Highland Beach

RECO’s admissions team works with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS for Spravato prior authorization. Documented TRD — two adequate antidepressant trials in the current episode with adequate dose and duration — is the standard bar for medical necessity. The office handles the appeals process directly when initial authorizations are denied, which is a routine step for esketamine and not a signal that treatment is inappropriate.

The seven-mile A1A route from Highland Beach matters more than it sounds. Patients on a twice-weekly induction schedule spend eight consecutive weeks driving to sessions, and a twelve-minute door-to-door commute is a meaningful adherence factor for residents of Bel Lido Isle, Toscana, and the Penthouse corridor.

Serving residents of: Bel Lido Isle, Boca Cove, Ocean Cove, Toscana, Penthouse.